Powered by


Mar 21, 2017 - AWP OTS (Original Text Service)

FDA APPROVES XADAGO® (SAFINAMIDE) FOR PARKINSON'S DISEASE (PD) PATIENTS First New Chemical Entity (NCE) approved for PD patients with motor fluctuations in the U.S.A. in over a decade Milan, Italy and Morristown, NJ, U.S.A., - March 21, 2017 - Newron Pharmaceuticals S.p.A. (http://www.newron.com/) ("Newron", SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain, and its partners Zambon S.p.A.

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox